6505--PET Radiopharmaceuticals for Nuclear Medicine Department at the Buffalo VA Medical Center

The Department of Veterans Affairs Network Contracting Office 02 is seeking a contractor to provide PET Radiopharmaceuticals for the Buffalo VA Medical Center through a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The solicitation requires a Nuclear Regulatory Commission or FDA-licensed radiopharmacy capable of supplying five specific radiopharmaceutical products: FDG, Cu64 (DetectNet), F18-DCFPyl PSMA (Pylarify), Ga-68 DOTATATE, and F18 Florbetaben (Neuraceq). Potential contractors must have at least three years of business experience and be able to perform daily deliveries to the VA Western NY Healthcare System. The contract will be awarded through a full and open competition under NAICS code 325412, with proposals evaluated based on technical capability, past performance, and pricing. Quotes are due by March 28, 2025, at 4:00 PM EST, and will be submitted electronically to Contracting Officer Jonathan Kilgore.

The solicitation does not include any specific set-aside designations, allowing for broad competition among potential vendors. The contract has a guaranteed minimum value of $100,000 and will cover the period from April 15, 2025, through April 14, 2028. Estimated annual usage quantities for the radiopharmaceuticals range from 2 to 1,000 doses, depending on the specific product. The place of performance is located at 3495 Bailey Ave, Buffalo, NY 14215, which is the Buffalo VA Medical Center. The small business size standard for this procurement is set at 1,300 employees, and the contract requires strict compliance with federal and state regulations for handling, packaging, and quality control of radioactive materials. No incumbent provider is mentioned in the available documentation, suggesting this may be a new procurement approach for the VA.